Actualités

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

Novo Nordisk is finally getting one up on its biggest rival.

The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may not be the company that makes the drug.

The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures.

Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.

All three can be bought on the dip.

Novo Nordisk (NVO) closed the most recent trading day at $51.48, moving +1.82% from the previous trading session.

Novo Nordisk (NYSE:NVO) received European Commission marketing authorization for its oral Wegovy pill for weight management. The approval covers the European Union and represents the first GLP-1 receptor agonist in pill form cleared for this use in the region. This decision follows growing use of obesity therapies in the U.S. and other key markets. Novo Nordisk is already a major player in diabetes and obesity care, and the oral Wegovy pill gives the company another way to reach patients...

Novo Nordisk wins EC approval for a once-daily oral Wegovy pill for obesity, expanding its EU franchise with the first GLP-1 tablet for weight management.

Novo Nordisk is relying on first-mover advantage in the obesity pill arena to close the gap on Eli Lilly.

European equities traded in the US as American depositary receipts were slightly lower on Thursday m

PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth, acquisitions and a low valuation with a high dividend.

FDA advisors will debate the merits of seven peptides next week. The discussion could have an impact on Eli Lilly and Novo Nordisk.

Faced with the dual pressures of shifting consumer habits and emerging health trends, General Mills finds itself in a challenging market position.

Novo Nordisk is under fresh scrutiny as analysts adjust their price targets, with a fair value estimate moving from DKK 309.77 to DKK 316.91. This shift reflects a broader rethink of growth and risk assumptions, as analysts weigh more cautious revenue expectations against their updated view of what the stock might be worth. As you read on, you will see how to interpret these changing targets and what they could mean for your own view of Novo Nordisk. Stay updated as the Fair Value for Novo...

Vivani Medical (NASDAQ:VANI) said it is preparing to begin human testing of its semaglutide implant in August and highlighted a recently announced agreement with Novo Nordisk to evaluate the company’s implant technology. Adam Mendelsohn, co-founder, CEO and director of Vivani Medical, said the past

Wegovy Pill Wins Big as Eli Lilly Rollout Lags

Wegovy captured about 89% of weekly prescriptions.

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the

Oral Wegovy is now cleared in all EU member states.

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State

Novo Nordisk (NVO) said Wednesday the European Commission granted marketing authorization for Wegovy

Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.

European equities traded in the US as American depositary receipts were rising on Wednesday morning,

UBS has told clients the recent sell-off in artificial intelligence stocks looks inconsistent with the fundamentals and has pushed AI themes back to the top of its rankings. The bank's 'Theme-ometer', a quantitative framework that scores investment themes across macro conditions, earnings,...

Microsoft Corporation (NASDAQ:MSFT) is one of the high-growth wide-moat stocks to buy. On July 2, Microsoft launched Microsoft Frontier Company with $2.5 billion in funding to help large customers deploy AI systems around their own data and workflows. Reuters reported that the unit will begin by working with clients including Unilever and Novo Nordisk and […]

The company’s second upgrade to annual guidance is a sign that companies are scrambling for its semiconductor-making tools in the race to build AI infrastructure.

Don't wait until clinical milestones send their share prices soaring.

Since its obesity pill Foundayo hit the market in April, Lilly has captured about 11% of the prescription volume for new pills, according to the latest weekly data. Novo Nordisk’s Wegovy pill, which launched in January, commands the rest. It is a remarkable turn of events for the near $80 billion anti-obesity market, among the hottest in the industry.

Novo Nordisk presented long-term phase 3 data for denecimig (Mim8) prophylaxis in hemophilia patients, showing sustained efficacy, safety, and treatment satisfaction. The company also reported first efficacy and safety results for concizumab (Alhemo) in pediatric hemophilia patients under 12, indicating reduced bleeding and manageable safety. These trial readouts expand evidence across both adult and pediatric populations, supporting Novo Nordisk’s position in rare blood disorders. For...